Mostra el registre parcial de l'element
dc.contributor.author | Freyer, Gilles |
dc.contributor.author | Kalinka-Warzocha, Ewa |
dc.contributor.author | Syrigos, Konstantinos |
dc.contributor.author | Marinca, Mihai |
dc.contributor.author | Tonini, Giuseppe |
dc.contributor.author | Ng, Say Liang |
dc.contributor.author | Wong, Zee Wan |
dc.contributor.author | Salar Silvestre, Antonio |
dc.contributor.author | Steger, Guenther |
dc.contributor.author | Abdelsalam, Mahmoud |
dc.contributor.author | DeCosta, Lucy |
dc.contributor.author | Szabo, Zsolt |
dc.date.accessioned | 2015-11-10T11:22:43Z |
dc.date.available | 2016-10-31T03:00:04Z |
dc.date.issued | 2015 |
dc.identifier.citation | Freyer G, Kalinka-Warzocha E, Syrigos K, Marinca M, Tonini G, Ng SL. et al. Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia. Med Oncol. 2015 Oct;32(10):236. doi: 10.1007/s12032-015-0682-z. |
dc.identifier.issn | 1357-0560 |
dc.identifier.uri | http://hdl.handle.net/10230/25031 |
dc.description.abstract | Febrile neutropenia (FN) is a potentially fatal complication of chemotherapy. This prospective, observational study describes physicians' approaches toward assessing FN risk in patients receiving chemotherapy regimens with an intermediate (10-20 %) FN risk. In the baseline investigator assessment, physicians selected factors considered important when assessing overall FN risk and deciding on granulocyte colony-stimulating factor (G-CSF) primary prophylaxis (PP). Physicians then completed patient assessments using the same lists of factors. The final FN risk scores and whether G-CSF PP was planned were reported. The final analysis included 165 physicians and 944 patients. The most frequently considered factor in both assessments was chemotherapy agents in the backbone (88 % of investigator and 93 % of patient assessments). History of FN (83 %), baseline laboratory values (76 %) and age (73 %) were commonly selected at baseline, whereas tumor type (72 %), guidelines (62 %) and tumor stage (43 %) were selected most during patient assessments. Median investigator-reported FN risk threshold for G-CSF PP was 20 % (range 10-85 %). G-CSF PP was planned in 82 % of patients with an FN risk at or above this threshold; therefore, almost one-fifth of qualifying patients would not receive G-CSF PP. Physicians generally follow guidelines, but also consider individual patient characteristics when assessing FN risk and deciding on G-CSF PP. A standardized FN risk assessment may optimize the use of G-CSF PP, which may minimize the incidence of FN in patients undergoing chemotherapy with an intermediate FN risk. ClinicalTrials.gov Identifier: NCT01813721. |
dc.description.sponsorship | Funding for this support was provided by Amgen (Europe) GmbH. |
dc.format.mimetype | application/pdf |
dc.language.iso | cat |
dc.publisher | Springer |
dc.relation.ispartof | Medical Oncology. 2015 Oct;32(10):236 |
dc.rights | c) Springer ( The original publication is available at www.springerlink.com) |
dc.subject.other | Quimioteràpia |
dc.subject.other | Neutropènia |
dc.title | Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia. |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | http://dx.doi.org/10.1007/s12032-015-0682-z |
dc.rights.accessRights | info:eu-repo/semantics/openAccess |
dc.type.version | info:eu-repo/semantics/acceptedVersion |